Efficacy and tolerability of intensity-modulated radiotherapy (IMRT) with cisplatin (CDDP) versus cetuximab (CTX) and nimotuzumab (NTZ) for Stage II-IVb Nasopharyngeal Carcinoma (NPC).
Phase of Trial: Phase IV
Latest Information Update: 23 Oct 2017
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin (Primary) ; Nimotuzumab (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 23 Oct 2017 New trial record
- 15 Sep 2017 Results of multivariate analysis and subgroup analysis assessing Efficacy and safety were compared between the CTX/NTZ and CDDP groups, were published in the International Journal of Cancer.